AP NEWS

Anova Launches Crowdfunding Campaign to Help Patients Most in Need

September 19, 2018

LONDON & CHICAGO--(BUSINESS WIRE)--Sep 19, 2018--Anova Enterprises, LLC (Anova), an organization dedicated to fixing what is broken in clinical trials, has announced a crowdfunding campaign to raise money to build a software application to help patients with serious or life-threatening conditions access promising new therapies.

Anova’s patient software application will form part of a platform that will allow patients to match to a clinical trial based upon their personal diagnosis, omic features and treatment history. Clinical trial matches will be to local, open and accruing clinical trials. Patients will be able to communicate with an investigator to volunteer to participate in a specific study. For patients who have no viable clinical trial opportunity, the software will match patients to promising investigational products and facilitate Compassionate Use requests.

It is hard for patients to access new treatments, oftentimes because it is difficult to search products and match those therapies to their condition. Once a match is made, it can be additionally frustrating to find an open and accruing clinical trial. The Anova application is designed to address these challenges, and empower patients by taking the guess work out of the question of what to do when standard of care treatment has been exhausted. Anova will use money generated through crowdfunding to build important parts of the solution for patients, address barriers to accessing promising new treatments and provide more control for patients over treatment choices.

Christopher Beardmore, CEO of Anova remarked, “In supporting patients access to promising new treatments, the potential benefit for patients is clear. There are also benefits for participating physicians and manufacturers. Anova’s program will help patients understand the potential therapies that may help them and take more control of the treatment choices that may be available to them, often when those choices are limited. Anova is intent on supporting patients’ access to research wherever they receive care, and this application is an important building block in achieving that.”

The program has been designed with the support of leading Institutional Review Boards and patient advocacy groups in consultation with the Food and Drug Administration.

To donate to the campaign, go to https://igg.me/at/anova. Patients who want help making Compassionate Use requests or preparing protocol/consent materials for an approved request are encouraged to participate.

ENDS

About Anova Anova Enterprises, LLC (Anova) is accelerating clinical development with an approach designed to disrupt and transform the traditional drug development model, using SaaS-based technology to enable efficient design, networking, management and conduct of clinical studies as part of a learning system that speeds product development, reduces cost and increases the chance of product success (i.e., marketing approval).

www.anovaevidence.com Twitter feed at @anovaevidence

View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005317/en/

CONTACT: Anova

UK

Martin Walsh

martin@anovaevidence.com

or

US

Chris Beardmore

chris@anovaevidence.com

KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA ILLINOIS

INDUSTRY KEYWORD: TECHNOLOGY INTERNET SOFTWARE HEALTH PHARMACEUTICAL PHILANTHROPY PROFESSIONAL SERVICES FINANCE FUND RAISING MANAGED CARE

SOURCE: Anova

Copyright Business Wire 2018.

PUB: 09/19/2018 09:00 AM/DISC: 09/19/2018 09:01 AM

http://www.businesswire.com/news/home/20180919005317/en

AP RADIO
Update hourly